Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

BRCA1 and BRCA2 5' noncoding region variants identified in breast cancer patients alter promoter activity and protein binding

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. A mutation update on the LDS-associated genes TGFB2/3 and SMAD2/3

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Structural and sequence variants in patients with Silver-Russell syndrome or similar features-Curation of a disease database

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Mutational Spectrum in a Worldwide Study of 29,700 Families with BRCA1 or BRCA2 Mutations

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Monogenic diabetes syndromes: Locus-specific databases for Alström, Wolfram, and Thiamine-responsive megaloblastic anemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Completeness of RET testing in patients with medullary thyroid carcinoma in Denmark 1997-2013: a nationwide study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Replication of newly proposed TNM staging system for medullary thyroid carcinoma: a nationwide study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Using microarray-based subtyping methods for breast cancer in the era of high-throughput RNA sequencing

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Incidence and prevalence of multiple endocrine neoplasia 2A in Denmark 1901-2014: a nationwide study

    Research output: Contribution to journalJournal articleResearchpeer-review

  • ENIGMA consortium
View graph of relations

The widespread use of next generation sequencing for clinical testing is detecting an escalating number of variants in noncoding regions of the genome. The clinical significance of the majority of these variants is currently unknown, which presents a significant clinical challenge. We have screened over 6,000 early-onset and/or familial breast cancer (BC) cases collected by the ENIGMA consortium for sequence variants in the 5' noncoding regions of BC susceptibility genes BRCA1 and BRCA2, and identified 141 rare variants with global minor allele frequency < 0.01, 76 of which have not been reported previously. Bioinformatic analysis identified a set of 21 variants most likely to impact transcriptional regulation, and luciferase reporter assays detected altered promoter activity for four of these variants. Electrophoretic mobility shift assays demonstrated that three of these altered the binding of proteins to the respective BRCA1 or BRCA2 promoter regions, including NFYA binding to BRCA1:c.-287C>T and PAX5 binding to BRCA2:c.-296C>T. Clinical classification of variants affecting promoter activity, using existing prediction models, found no evidence to suggest that these variants confer a high risk of disease. Further studies are required to determine if such variation may be associated with a moderate or low risk of BC.

Original languageEnglish
JournalHuman Mutation
Volume39
Issue number12
Pages (from-to)2025-2039
Number of pages15
ISSN1059-7794
DOIs
Publication statusPublished - Dec 2018

ID: 56674181